


The 2019 Rare Neurological Disease Special Report Is Now Available

This 5th annual issue is the largest to date and focuses on the progress in medical science, genetics, and neuromuscular diseases

Parsippany, NJ – April 16, 2019 – Frontline Medical Communications (FMC) is pleased to announce the publication of the 2019 ***Neurology Reviews Rare Neurological Disease Special Report***. Produced in collaboration with the National Organization for Rare Disorders (NORD), this 5th annual issue is now available as a digital edition online, in print, and via the ***Neurology Reviews*** mobile app.

Published each year to commemorate Rare Disease Day, the ***Rare Neurological Disease Special Report*** is a joint endeavor in which ***Neurology Reviews*** and **NORD** partner to keep the busy clinician abreast of the latest diagnostic tools and medical therapies available to manage and treat rare neurological medical conditions. With more than 7,000 rare diseases identified and more than half of the medical treatments approved by the FDA last year for rare diseases, health care professionals need easily accessible, reliable resources to stay informed —the ***Rare Neurological Disease Special Report*** serves as a valued reference.



Nearly a third of the 2019 issue focuses on the latest advances in clinical genetic testing, newborn screenings, and gene-based therapies. Information and resources on gene therapy are a particular focus; of note are the profile of the New York Genome Center and the Alliance for Regenerative Medicine's article on cell and gene therapy. Additional highlights include NORD's educational, research, and advocacy efforts; the pioneering work of the pharmaceutical industry and disease-state medical, genetic, and patient-focused associations and

societies; the promising drug pipeline for rare neuromuscular diseases – spinal muscular atrophy, amyotrophic lateral sclerosis (ALS), Lambert-Eaton myasthenic syndrome (LEMS), Huntington's disease, Charcot-Marie-Tooth disease, and Duchenne muscular dystrophy; and NIH tools, registries, and educational materials.

Elizabeth Katz, Publisher of ***Neurology Reviews***, has spearheaded the development of this key resource since inception. "It has been such a rewarding experience to bring together key stakeholders whose common goals are focused on helping patients with rare disease and their families find life-changing solutions," she said. In announcing the issuance, Ms. Katz also acknowledged the tireless efforts of the editorial team, led by Glenn Williams, VP, Group Editor. Ms. Katz and Mr. Williams also acknowledged the work of Ronald DeBellis, PharmD, the students of the Keck Graduate Institute who contributed articles, and the staff of NORD.

Annual research on the ***Rare Neurological Disease Special Report*** confirms a high level of awareness and readership (84%); nearly all agree the quality of material is useful/effective; and more than two-thirds strongly agree it broadens their understanding of certain rare diseases and the difficulties surrounding symptom identification, diagnosis, and family life.

To learn more about the rare disease initiatives of ***Neurology Reviews*** and the NORD partnership, contact Elizabeth Katz at 973-224-7951 or ekatz@mdedge.com. Details and information on all FMC/MDedge digital brands, print

publications, and custom solutions are available at www.frontlinemedcom.com; visit weekly for the latest innovative programs and multimedia initiatives.

About *Neurology Reviews* and MDedge Neurology

Launched in 1993, *Neurology Reviews*® is the first and original news source in neurology. *Neurology Reviews*® has a 26-year history of providing independent, unbiased news to neurologists and clinicians interested in the neurosciences. *Neurology Reviews*® covers medical conferences and clinical research findings, as well as specialty trends, expert opinions, and the breadth of influences affecting the practice of neurology. Experienced medical journalists deliver timely, relevant, and insightful news affecting the practice of neurology and all its subspecialties. In addition to the monthly print issue reaching nearly 25,000 neurologists and clinicians interested in neuroscience, the *Neurology Reviews*® website www.mdedge.com/neurology, part of the MDedge™ web portal, features online ahead of print conference reporting, audio and video interviews, disease-specific microsites, self-assessment quizzes, supplements, sponsored educational programs, a calendar of relevant medical meetings, and a career center listing job openings around the country. *Neurology Reviews*® provides its content in print, through an App, on a mobile-friendly website, in digital editions, and through targeted e-blasts.

About the National Organization for Rare Disorders (NORD)®



The **National Organization for Rare Disorders (NORD)®** is the leading independent advocacy organization representing all patients and families affected by rare diseases. NORD is committed to the identification, treatment and cure of the more than 7,000 rare diseases that affect 25 to 30 million Americans. NORD began as a small group of patient advocates that formed a coalition to unify and mobilize support to pass the Orphan Drug Act of 1983. For 36 years, NORD has led the way in voicing the needs of the rare disease community, driving supportive policies and education, advancing medical research, and providing patient and family services for those who need them most. NORD represents more than 280 disease-specific member organizations and collaborates globally to raise awareness around rare disease and advance access to treatments for our community.

www.rarediseases.org.

About Frontline Medical Communications



Frontline Medical Communications Inc. is one of the healthcare industry's largest medical communications companies and a leader in digital, print, and live events. The Company leads in HCP-level targeting and is ranked 1st in combined web and print engagements. With **MDedge™**, our state-of-the-art integrated web portal, and audited email database, FMC meets the marketing challenges of our clients with superior reach, optimal sponsorship opportunities, and flexible advertising programs. We reach 1.2 million+ physicians, NPs, PAs, HCPs, and key healthcare decision makers through more than 30 media brands serving 20 distinct markets, who access our content through an array of digital, print, and face to face channels and social media platforms. FMC delivers award-winning, indexed, clinical reviews; practice and policy information; and medical news daily from on-site reporting at major medical meetings, many in collaboration with notable societies, medical associations, and opinion leaders. FMC produces live events, digital click-for-credit, and CME in affiliation with Global Academy for Medical Education, LLC (globalacademycme.com) and Hemedicus (www.hemedicus.com). Visit frontlinemedcom.com | [Twitter](#) | [Facebook](#) | [LinkedIn](#).

Contact:

Elizabeth Katz, Publisher, ekatz@mdedge.com, 973.224.7951

Frontline Medical Communications

Corporate office: 7 Century Drive, Suite 302

Parsippany, NJ 07054-4609 | Main: 973.206.3434 | Fax: 973.206.9378

www.frontlinemedcom.com | www.frontlinerates.com | General Email: sales@mdedge.com